Biolyse has a long standing experience in the development of new and generic injectables.
A new biologics facility, that is to be completed in early 2022, will extend our capability to produce large molecules such as monoclonal antibodies, therapeutic peptides and life protecting vaccines.
This division will also be able to support clients that aspire to bringing their innovative products to market.
Biolyse will offer accessibility to services such as:
manufacturing design and validations
scale-up manufacturing for clinical trial application
clinical trial management